在关键次要终点指标的比较中，服用36毫克Orforglipron的参与者体重减轻了19.7磅（减重比例达9.2%），而服用14毫克口服司美格鲁肽的参与者体重减轻了11.0磅（减重比例为5.3%）。这一数据凸显了礼来公司在研药物Orforglipron在体重管理方面的潜在优势。
在关键次要终点指标的比较中，服用36毫克Orforglipron的参与者体重减轻了19.7磅（减重比例达9.2%），而服用14毫克口服司美格鲁肽的参与者体重减轻了11.0磅（减重比例为5.3%）。这一数据凸显了礼来公司在研药物Orforglipron在体重管理方面的潜在优势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.